Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ATHE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.22
N/A
-0.00
vs -0.00
Q4.22
N/A
-0.00
vs -0.00
Q1.23
N/A
-0.00
vs NA
Q2.23
N/A
-0.00
vs -0.00
Q3.23
N/A
-0.00
vs NA
Q4.23
N/A
-0.00
vs -0.00
Q1.24
N/A
-0.00
vs -0.00
Q2.24
N/A
-0.00
vs -0.00
Q3.24
N/A
-0.00
vs -0.00
Q4.24
N/A
-0.00
vs -0.00
Sales Growth
YoY
Current
Estimates
Q2.22
+13%
2.8M vs 2.5M
Q4.22
+1%
2.4M vs 2.4M
Q1.23
NA
765.2K vs NA
Q2.23
-45%
1.5M vs 2.8M
Q3.23
NA
950.4K vs NA
Q4.23
-20%
1.9M vs 2.4M
Q1.24
+38%
1.1M vs 765.2K
Q2.24
+38%
2.1M vs 1.5M
Q3.24
-16%
803K vs 950.4K
Q4.24
-58%
803K vs 1.9M
Return on Equity
QoQ
Q2.21
-22%
-0.22
vs -0.25
Q4.21
-16%
-0.16
vs -0.22
Q2.22
-18%
-0.18
vs -0.16
Q4.22
-29%
-0.29
vs -0.18
Q2.23
-25%
-0.25
vs -0.29
Q4.23
-37%
-0.37
vs -0.25
Q2.24
-91%
-0.91
vs -0.37
Q4.24
-92%
-0.92
vs -0.91
Institutionnal Ownership
QoQ
Q2.23
7
7
vs 7
NA
Q3.23
8
8
vs 7
14%
Q4.23
9
9
vs 8
13%
Q1.24
10
10
vs 9
11%
Q2.24
10
10
vs 10
NA
Q3.24
12
12
vs 10
20%
Q4.24
12
12
vs 12
NA
Q1.25
11
11
vs 12
-8%
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
Quote Panel
Key Metrics
Forecast
39%2025-Revenue
-95%2025-EPS
82%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Benchmark
downgradePrevious: Speculative Buy
2025-02-03
Now: Buy
Relative Strength
ATHE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.11 ( 2.64%)
Relative Strenght
89
Volume Buzz
-75%
Earning Acce
No
Dist 52w H.
29%